BRIEF-Oncomed Pharmaceuticals provides topline data from phase 2 trial on Tarextumab
August 30, 2016 at 09:17 AM EDT
* Topline data from phase 2 trial on Tarextumab in small cell lung cancer expected to be reported at end of 2016 or in early 2017 Source text for Eikon: Further company coverage:
